Mutations in the Kras2 gene are seen in both human and mouse lung adenocarcinomas. The protein product (p21 ras ) encoded by the Kras2 gene must be post-translationally modified at a terminal CAAX motif in order to be biologically active. In this study, we systematically investigated the chemopreventive efficacy of two different farnesyltransferase inhibitors (FTIs): one is a peptidomimetic (FTI-276) and the other is an imidazole (L778-123). Both FTIs are designed to inhibit the posttranslational modification of p21 ras proteins with a terminal CAAX motif. In a complete chemoprevention study, where the inhibitor was administered before carcinogen was given, and throughout the study, FTI-276 treatment significantly reduced both the tumor multiplicity by 41.7% (Po0.005), and the total tumor volume by 79.4% (Po0.0001). In the late treatment study, where mice were treated with an inhibitor 12 to 20 weeks after carcinogen administration, FTI-276 treatment resulted in a 60% reduction in tumor multiplicity and 58% reduction in tumor volume. Next, we examined the chemopreventive efficacy of a new FTI, L-778,123, on lung tumor development in A/J mice and transgenic mice with a dominant-negative p53 mutation and/or heterozygous deletion of Ink4a/Arf. Treatment of mice with L-778,123 for a period of 10 weeks from 20 weeks to 30 weeks post carcinogen initiation resulted in an B50% decrease in tumor multiplicity in wild-type mice and mice with a dominant-negative p53 mutation and/or heterozygous deletion of the Ink4a/Arf tumor suppressor genes. Interestingly, tumor volume was decreased B50% in wildtype mice and in mice with an Ink4a/Arf heterozygous deletion, while tumor volume was decreased B75% in animals with a dominant-negative p53 and in mice with both a p53 mutation and heterozygous deletion of Ink4a/ Arf. This result suggests that FTI exhibited a significantly (Po0.05) more efficacious chemopreventive effect in animals with alterations of p53 and Ink4a/Arf as contrasted with wild-type mice. Thus, FTIs are potent lung chemopreventive agents in both A/J mice and transgenic mice harboring a dominant-negative p53 and heterozygous deletion of Ink4a/Arf. In fact, L-778,123 is more effective in inhibiting primary lung progression in mice with a p53 mutation and/or an Ink4a/Arf deletion than in wild-type animals.
Mutations in the Kras2 gene are seen in both human and mouse lung adenocarcinomas. The protein product (p21 ras ) encoded by the Kras2 gene must be post-translationally modified at a terminal CAAX motif in order to be biologically active. In this study, we systematically investigated the chemopreventive efficacy of two different farnesyltransferase inhibitors (FTIs): one is a peptidomimetic and the other is an imidazole (L778-123). Both FTIs are designed to inhibit the posttranslational modification of p21 ras proteins with a terminal CAAX motif. In a complete chemoprevention study, where the inhibitor was administered before carcinogen was given, and throughout the study, FTI-276 treatment significantly reduced both the tumor multiplicity by 41.7% (Po0.005), and the total tumor volume by 79.4% (Po0.0001). In the late treatment study, where mice were treated with an inhibitor 12 to 20 weeks after carcinogen administration, FTI-276 treatment resulted in a 60% reduction in tumor multiplicity and 58% reduction in tumor volume. Next, we examined the chemopreventive efficacy of a new FTI, L-778,123, on lung tumor development in A/J mice and transgenic mice with a dominant-negative p53 mutation and/or heterozygous deletion of Ink4a/Arf. Treatment of mice with L-778,123 for a period of 10 weeks from 20 weeks to 30 weeks post carcinogen initiation resulted in an B50% decrease in tumor multiplicity in wild-type mice and mice with a dominant-negative p53 mutation and/or heterozygous deletion of the Ink4a/Arf tumor suppressor genes. Interestingly, tumor volume was decreased B50% in wildtype mice and in mice with an Ink4a/Arf heterozygous deletion, while tumor volume was decreased B75% in animals with a dominant-negative p53 and in mice with both a p53 mutation and heterozygous deletion of Ink4a/ Arf. This result suggests that FTI exhibited a significantly (Po0.05) more efficacious chemopreventive effect in animals with alterations of p53 and Ink4a/Arf as Introduction Lung cancer is the leading cause of cancer death in men and women in the US (Minna et al., 1989) . There is a strong correlation between lung cancer susceptibility and exposure to tobacco-related carcinogens (Sellers et al., 1992; Landis et al., 1998) . Molecular changes in proto-oncogenes and tumor suppressor genes have been detected in all stages of lung carcinogenesis. Mutations in the ras oncogenes have been implicated in the pathogenesis of several human cancers including lung, colon, and pancreatic (Bos, 1989) cancers. In particular, nonsmall cell lung carcinoma (NSCLC), which accounts for 75% of lung cancers, has been shown to harbor Kras2 mutations in 30-50% of all cases (Rodenhuis and Slebos, 1992) . Thus, blocking the effect of ras mutations has become one of the major strategies in cancer treatment and prevention.
Similar genetic changes seen in human lung cancers have also been observed in mouse lung tumors. Kras2 is frequently activated in both mouse lung adenomas and adenocarcinomas (You et al., 1989) . Alterations of other known tumor suppressors, such as p16, Rb, and p53, have been detected in lung tumors as well, although typically these have occurred later in tumor progression and often at lower frequencies (Herzog et al., 1997) . We have previously demonstrated an increased susceptibility to chemical induction of mouse lung, uterine, colon, and skin tumorigenesis in p53 transgenic mice Zhang et al., 2000 Zhang et al., , 2002a . The region containing the Ink4a/Arf locus on mouse chromosome 4 was frequently lost (50%) in lung carcinomas of various F 1 hybrid mouse strains (Herzog et al., 1997) . Furthermore, the Ink4a/Arf locus is homozygously codeleted in 12 of 16 (75%) mouse lung tumor cell lines (Herzog et al., 1996; McDoniels-Silvers AL et al., 2001 ). More recently, we provided functional evidence in vivo that heterozygous loss of Ink4a/Arf contributes to enhance lung tumor progression in mice (Zhang et al., 2002b) . In general, genetic changes found in mouse lung tumors have striking similarities to those existing in humans.
The Ras family of small GTP binding proteins is key to many signaling events in eukaryotes, including those for growth, differentiation, cytoskeletal organization, and apoptosis (Bos, 1989; Khosravi-Far and Der, 1994) . All Ras proteins are synthesized as inactive precursors, which must be post-translationally modified to be biologically active (Casey et al., 1989; Hancock et al., 1989) . The first step in the modification of Ras is the addition of a 15-carbon isoprenoid (farnesol) by farnesyltransferase (FTase) to the C-terminal cysteine of the CAAX motif (Hancock et al., 1989) . Therefore, potential strategies have been sought that selectively interfere with farnesylation of constitutively activated oncogenic proteins like Ras (Gibbs et al., 1993; Tamanoi, 1993; Lerner et al., 1995a and b) . There have been a series of reports on FTI as a potential cancer chemotherapeutic agent . In cell culture models, FTIs reverse many of the biological properties of ras-transformed cells, particularly Ha-ras or N-ras, including inhibition of anchorage-independent growth, and morphological reversion (Prendergast and Oliff, 2000; Sebti and Hamilton, 2000; Reuter et al., 2000) . These compounds also inhibited the growth of ras-transformed fibroblasts and human tumor cell lines transplanted into nude mice Reuter et al., 2000; Prendergast and Oliff, 2000) . Most in vitro studies have predicted that FTI would be cytostatic rather than cytotoxic. Previous studies with FTI-276 employing the human lung adenocarcinoma cell lines CaLu-1 and A-549, which bear a mutant Kras2 oncogene, demonstrated a growth inhibition of CaLu-1 cell xenografts (Sun et al., 1995 (Sun et al., , 1998 . We recently reported the in vitro evaluation of FTI-276 in four lung epithelial cell line, two of which were immortalized, C10 and E10, the latter harboring a p53 mutation (Lantry et al., 2000a) . The remaining cell lines, LM1 and LM2, were both tumorigenic and metastatic in mouse models, the latter of which harbors a 61st codon mutation in Kras2 (Lantry et al., 2000a) . The most normal cell lines, the C10, were the least affected, with a 22% reduction in growth rate over control (Lantry et al., 2000a) . The LM1 with wild-type ras had the greatest reduction in growth rate over control, at 64%, followed by the LM2 at 51%, and the E10 at 43% (Lantry et al., 2000b) . In vivo, FTIs treatment of mice carrying activated forms of Ha-ras, N-ras, or K-ras showed either tumor regression or tumor stasis (Kohl et al., 1995; Mangues et al., 1998; Omer et al., 2000) . For example, treatment of MMTV-H-ras mice with the FTI L-744,832 caused rapid tumor regression, treatment of MMTV-N-ras mice with FTI L-744,832 also caused tumor growth inhibition, while treatment of MMTV-Ki-rasB mice caused tumor stasis in mammary tumorigenesis (Kohl et al., 1995; Mangues et al., 1998; Omer et al., 2000) .
We had previously shown that FTI-276 exhibited a significant efficacy in a late treatment chemoprevention protocol in the A/J mouse lung tumor model (Lantry et al., 2000b) . In the present study, we determined the chemopreventive effect of FTI-276 in a complete chemoprevention protocol in the A/J mice, and we also determined the efficacy of another FTI inhibitor (L-778,123) in transgenic mice with various genotypes including wild-type mice, mice with a dominant-negative p53 mutation, mice with heterozygous deletion of the Ink4a/Arf locus and mice with both a p53 mutation and heterozygous deletion of the Ink4a/Arf locus. The significance of using transgenic mice that contain a dominant-negative p53 mutation and/or heterozygous deletion of the Ink4a/Arf is the fact that mouse lung tumor progression in these transgenic mouse models will involve three major genetic alterations (Kras2, p53, and Ink4a/Arf) commonly found in human lung NSCLC. Inactivation of p16 by hypermethylation and homozygous deletion has been detected in the majority of NSCLCs (Merlo et al., 1995) . Other common changes include p53 mutations and Rb gene inactivation that have been seen frequently in invasive carcinomas (Chiba et al., 1990; Xu et al., 1991) .
In the present study, we crossed p53 transgenic mice with heterozygous Ink4a/Arf deficient mice to investigate the functional role of p53 and Ink4a/Arf genes in mouse lung tumorigenesis. Use of these mice with either a germline mutant p53 transgene (p53 val135/wt ), heterozygous Ink4a/Arf deficient, or both, on a A/J background, in conjunction with the lung-specific chemical carcinogens allows us to evaluate FTI as a chemopreventive agent against lung cancer in a potentially more relevant model than the standard A/J mouse model.
Results
Effect of FTI-276 on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in A/J mice The effect of late treatment protocol for FTI-276 was previously examined in the A/J mouse lung tumor model. Mouse lung tumors were initiated with a single injection of NNK (100 mg/kg/body weight), and monitored for 18 weeks. The dependability of the pellet treatment was assessed in a pharmacokinetic study, in which mice treated with time-release pellets showed a cumulative average serum level of 1.68 mg/ml over a 30-day period (Lantry et al., 2000b) . In this earlier study, FTI-276 was delivered daily from time-release pellets for 30 days to the animals after they had been initiated with NNK for 18 weeks. As summarized in Figure 1 , and our published data (Lantry et al., 2000b) , FTI-276 delivered by time-release pellet reduced the lung tumor incidence by 42% (Po0.01) (Lantry et al., 2000b) , the multiplicity by 60% (Po0.01), and the tumor load by 58% (Po0.05) (Lantry et al., 2000b , Figure 1 ). In the present study, we examined the effect of complete chemoprevention treatment protocol for FTI-276 and the results are summarized in Figure 1 . FTI-276 pellets designed to deliver a daily dose equivalent to 40 mg/kg/body weight over 30 days were implanted subcutaneously into 5-week-old male A/J mice, once a month for four consecutive months. The mice were initiated with a tobacco specific carcinogen NNK during weeks 2 and 3. The multiplicity of tumors was significantly reduced in the treatment group with a reduction of 41.7% over control (Po.005) (Figure 1a) . In control mice, the average tumor number per mouse was 17. Characterization of a transgenic mouse lung tumor model with alterations in p53 and Ink4a/Arf p53 transgenic mice carrying a dominant-negative mutation (Ala 135 Val) were crossbred with heterozygous Ink4a/Arf-deficient mice. F 1 mice with four genotypes,
, and p53
, were initiated with a single dose of benzo(a)pyrene [B[a]P] (100 mg/kg body weight) or vehicle control (tricapryline), and monitored for 30 weeks. In the tricaprylintreated group, lung tumor multiplicity was similar in all groups of mice with various genotypes (Figure 2 ). In B[a]P treated groups, B[a]P produced an average of 12-13 tumors in wild-type (p53
) mice, and 21-23 tumors in mice with a p53 dominant negative mutation and in compound mice with both the p53 mutation and the INK4A deficiency ( Figure 2a ). There is no significant difference in tumor multiplicity between wild-type and heterozygous Ink4a/Arf-deficient mice. However, there is a significant increase in tumor size in heterozygous Ink4a/Arf-deficient (p53
) mice compared with that from wild-type (p53 (Figure 2a ). In addition, a synergistic effect of dominant-negative p53 combined with heterozygous loss of Ink4a/Arf was significantly more striking in the B[a]Ptreated groups causing an B30-fold increase in total tumor volume ( Figure 2b ). More notably, the majority of the large lung tumors (B80%) from the p53
þ /À mice were adenocarcinomas. In contrast, less than 10% of the lung tumors from the wild-type mice were adenocarcinomas, whereas B50% of the lung tumors from mice that were heterozygous Ink4a/Arfdeficient without the p53 mutation were adenocarcinomas. As shown in Figure 3 (b,d,f), mouse lung adenocarcinomas are composed of cells with varying degrees of differentiation with most cells relatively undifferentiated relative to lung adenomas ( Figure  3a ,c,e). There is a complete loss of normal alveolar architecture and the nuclear/cytoplasmic ratio is increased in the carcinomas (Figure 3b,d,f) . Nuclear crowding and cytologic atypia are present and there is heterogeneity of growth patterns. Invasion into adjacent bronchioles or vessels is also observed (Figure 3b ). These results suggest that dominant-negative p53 and Ink4a/Arf deficiency synergistically promote lung tumor progression. More importantly, this is the first transgenic mouse model that involves three major genetic In the second set of experiments, a new FTI, L-778,123, was examined for chemopreventive efficacy on lung tumor development in A/J mice and transgenic mice with a dominant-negative p53 mutation and/or heterozygous deletion of the Ink4a/Arf. Mice with four genotypes, p53
, were initiated with a single dose of B[a]P (100 mg/kg body weight) or vehicle control (tricapryline), and monitored for 20 weeks. Starting at 20 weeks postinitiation with B(a)P, L-778,123 was administered daily, 5 days/week for 10 weeks. As shown in Figure 4a , L-778,123 delivered by subcutaneous injection reduced the lung tumor multiplicity by 43-47% (Po0.01) in all four genotypes of mice when compared with B[a]P control groups. The effects on tumor volume were more interesting and surprising (Figure 4b ). Because wildtype mice (p53
) genotypes had a decrease in total tumor volume of roughly 50% (Po0.01) (Figure 4b ). In contrast, mice with a p53 mutation (p53
) had rough 75% reduction in tumor volume (Figure 4b ). The significance of percent changes were calculated using a Z-statistics for proportions and the data showed that these reductions on tumor load in p53
Ink4a/Arf þ /À mice are significantly different from the tumor reductions in p53 wild-type mice (Po0.05, Po0.01, respectively). This result indicates that L-778,123 inhibits B[a]P-induced mouse lung tumor growth more effectively in mice with defects in p53 and Ink4a/Arf.
Frequency and type of mutations in the Kras2 gene in tumors treated with and without FTI As shown in Table 1 , mutation analysis showed that eight out of 11 lung tumors from wild-type mice treated with B[a]P, and 10 out of 11 lung tumors from the B[a]P/ L-778,123 group were positive for 12th codon Kras2 mutations. The frequency and type of mutations in the Kras2 gene was similar in the group treated with L-778, 123 to those in the B[a]P control group. The result is consistent with our previous observation that eight out of nine tumors from tumor-bearing animals treated with FTI-276 and all of the tumors (7/7) from the control group were positive for Kras2 mutations at the 12th codon of the Kras2 gene without a significant difference in the frequency and type of mutations in the Kras2 gene between the group treated with FTI-276 as those in the control group (Lantry et al., 2000b) . Thus, there is no significant difference in the incidence and types of mutations between tumors from animals treated with an FTI (either FTI-276 or L-778,123) and tumors from control animals.
Discussion
There are three striking aspects in the present study. First, the results from this study clearly demonstrate the efficacy of FTIs against lung cancer that contains a Kras2 mutation, a p53 mutation, and/or Ink4a/Arf deletion. This is important since there have been concerns that the post-translational modification of Kras2, unlike Ha-ras and N-ras, cannot be completely blocked by inhibition of farnesylation. Nonetheless, lung tumors with Kras2 mutations are susceptible to FTIs. This observation seems to support the evidence that the FTI's primary targets may be RhoB (Du et al., 1999) and the proteins involved in the PI3K/AKT2 pathway (Jiang et al., 2000) rather than ras proteins themselves. Second, the efficacy of FTI -276 was similar when treatment was initiated either at the time of NNK 
Effect of FTI on lung tumorigenesis in transgenic mice Z Zhang et al administration or when treatment was initiated 18 weeks after NNK. These results imply that the primary inhibitory effects of FTIs are not during the phases of tumor initiation or early tumor progression, but rather on later phases of tumor progression. One should be aware that in the standard A/J model, virtually all of the tumors observed are adenomas. Third, in examining the therapeutic effects of L-778,123, we observed that the agent was more effective in inhibiting lung tumors with a dominant-negative p53 mutation or in compound mice with both a dominant-negative p53 mutation and heterozygous deletion of the Ink4a/Arf locus. This is quite important since mutations in p53 are commonly associated with resistance to therapy. Furthermore, p53 is perhaps the most commonly mutated gene in human tumors and is mutated early in tumor progression in certain cancers such as head and neck cancer and lung cancer. Agents that are effective in the face of this mutation are particularly appealing. Previous reports on the efficacy of FTIs in cell culture vary widely between investigators. Even studies using the same Kras2 mutant cell line report an opposite effect when treated with FTIs. For example, Gu et al. (1999) found that in the HCT116 colon carcinoma cell line, an FTI (A-170634) inhibited Ras processing and blocked anchorage-dependent and independent growth. Whereas in another study with the same cell line, Nagasu et al. (1995) , found that the FTI B965 did not block tumor growth, nor processing of Kras2. In our own in vitro studies, we found that FTI-276 exhibited growth inhibition in mouse lung epithelial cell lines: one contained an activating Kras2 mutation, while another had a Kras2 mutation and a p53 mutation. Employing anchorage-dependent growth as a primary end point, we found that the dose required to reach the ED 50 is greater for an FTI than a GGTI (Lantry et al., 2000a) . These findings demonstrate the difficulties in interpreting results of in vitro studies where questions of pharmacokinetics, stromal interactions, and/or potentially unique combinations of genotypic changes routinely observed in vivo may not come into play.
We have previously demonstrated that FTI-276 is chemopreventive in A/J mice using a late treatment protocol (Lantry et al., 2000b) . The mechanism(s) includes a decrease in proliferation and an increase in apoptosis in the treated tumors, but with minimal effects on normal lung tissue (Lantry et al., 2000a) . FTI-276 did not strongly reduce the initiation of tumors, since the multiplicity of tumors was only slightly reduced. However, there was a significant difference in tumor size between the treated and untreated controls consistent with the decreased proliferation and increased apoptosis we previously observed. The present study carefully and systematically investigated the chemopreventive efficacy of two FTIs in the best available in vivo mouse lung tumor models. A complete chemoprevention study was performed with FTI-276 in A/J mice, and a significant inhibition of lung tumorigenesis was observed. This result is consistent with the concept that FTIs act primarily on tumor progression. In a transgenic mouse model with a dominant-negative p53 mutation and/or heterozygous deletion of the Ink4a/ Arf, we found that L-778,123 was not only effective in preventing lung tumorigenesis in mice with all genotypes but also exhibited efficacy (B75% reduction in lung tumor volume) in animals with either a dominantnegative p53 or both a p53 mutation and heterozygous deletion of Ink4a/Arf.
There is increasing evidence that FTIs induce regression of tumors by multiple mechanisms, including the activation of apoptotic pathways or by cell cycle alterations (Barrington et al., 1998; Brassard et al., 2002; Crespo et al., 2002) . Barrington et al. (1998) demonstrated that FTI could induce dramatic regression of mammary and salivary carcinomas in mouse mammary tumor virus (MMTV)-v-Ha-ras transgenic and p53-deficient mice. They also showed that the inhibitory effect was mediated by both the induction of apoptosis and an increase in G1 with a corresponding decrease in the S-phase fraction in a p53 independent manner (Barrington et al., 1998) . A study of two human lung cancer cell lines showed that the ability of FTIs to inhibit bipolar spindle formation is not dependent on p53 mutation status since both wild-type and mutant p53 cells were equally affected (Crespo et al., 2002) . Taken together, these results demonstrated that the ability of FTI to inhibit tumor growth and/or accumulate cells in G1 is independent of a p53 mutation or heterozygous loss of p16 or both. In fact, we have shown that FTIs exhibited an increased efficacy against lung progression in mice with a dominant-negative p53 or both a p53 mutation and heterozygous deletion of Ink4a/Arf. This observation is consistent with the finding that p53-deficient cells were sensitized to the effects of DNA-damaging agents as a result of the failure to induce expression of the cyclin-dependent kinase inhibitor p21 (Bunz et al., 1999) . However, the exact mechanism for the increased efficacy of FTIs Approximately equal numbers of males and females were used, with no significant difference in tumor multiplicity between the sexes. In B[a]P-treated groups, there are 48
P-and L-778,123-treated groups, there are 21 Effect of FTI on lung tumorigenesis in transgenic mice Z Zhang et al against lung cancer progression in p53 and p53/Ink4a/ Arf is not clear at present. Finally, we described a new mouse model for human adenocarcinomas that includes alterations in commonly altered genes, for example, Kras2, p53, and Ink4a/Arf. Mutation or deletions of the Kras2, p53, and Ink4a/Arf tumor suppressor genes are the most common genetic defect detected in human lung cancer. p53 transgenic mice carrying a dominant-negative mutant p53 val135/wt were crossed with heterozygous Ink4a/Arf-deficient mice, on an A/J background. When these mice were treated with lung-specific chemical carcinogens, lung tumors were generated that contain mutated Kras2, p53 or/and loss of Ink4a/Arf genes. In agreement with our previous studies (Zhang et al., , 2002b , we found that mice with heterozygous deficiency of Ink4a/Arf exhibited a striking enhancement in lung tumor progression 30 weeks after carcinogen treatment when compared to their respective wild-type mice. A germline p53 mutation increased both tumor number and tumor volume 30 weeks postinitiation. More notably, our results showed that most of the tumors in compound p53
þ /À mice were larger and histologically more advanced adenocarcinomas. Taken together, these results strongly suggest that germline p53 mutation and deficiency of Ink4a/Arf exhibit an enhanced susceptibility to lung tumorigenesis, and mutant p53 acts synergistically with the deletion of Ink4a/Arf to accelerate the development of undifferentiated malignant lung tumors. The models described here would appear particularly relevant to examining potential chemopreventive or chemotherapeutic agents employing an in situ model with a number of the known mutations relevant to lung adenocarcinomas in humans. 
Materials and methods

Chemicals
Animal models
A/J mice were obtained from the Jackson Laboratories (Bar Harbor, ME, USA).
The N10(A/J Â UL53-3) mice are 10 times backcross UL53-3 mice (p53 transgenic mice) to the A/J strain. UL53-3 mice (on FVB background) carrying a 135val p53 mutation were obtained from National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA. The animals were paired to set up breeding colonies for production of (A/J Â UL53-3) F 1 mice and further to cross breed with A/J mice. After 10 generations of backcrossing to A/J mice, heterozygote N10(A/J Â UL53-3) p53 þ /À mice were used as breeder to generate the N10(A/J Â UL53-3) Â N6(A/J Â Ink4a/ArfKO) F 1 mice.
Ink4a/Arf nullizygous mice were obtained from Dana Faber Cancer Institute, (Boston, MA, USA) and have been rederived onto the A/J background through six generations of backcrossing. The A/J mouse is highly susceptible to lung tumor induction by mouse carcinogens. Since the tumor spectrum found in several knockout mice was similar including fibrosarcomas, lymphomas, and other types of sarcomas, the mouse background may partially contribute to the observed tumor spectrum. By using the A/J mouse as background, we are hoping that most of the resulting tumors developed in these mice will be lung tumors as seen in p53 transgenic mice . After six generations of backcrossing to A/J mice, heterozygote N6(A/J Â Ink4a/Arf KO) mice were used as breeder to generate the N10(A/J Â UL53-3) Â N6(A/J Â Ink4a/Arf KO) F 1 mice. Theoretically, N10(A/J Â UL53-3) mouse is 99.9% A/J background and N6(A/J Â Ink4a/Arf KO) mouse is 98.44% A/J background (Markel et al., 1997) .
Genotyping
Tail clippings from each N10(A/J Â UL53-3) Â N6(A/J Â Ink4a/Arf KO) F 1 mice were homogenized and incubated overnight at 371C in lysis solution (pronase 0.4 mg/ml, 10% sodium dodecylsulfate (w/v), 10 mm Tris, 400 mm NaCl, and 2 mm EDTA) followed by phenol-chloroform extraction and precipitation with ice-cold alcohol. To distinguish the p53 transgenic mice from nontransgenic littermates, DNA was extracted from the F 1 mice tail by the proteinase K-sodium dodecylsulfate method, and was genotyped using polymerase chain reaction (PCR)-RFLP method as described previously . Ink4a/Arf genotypes of the mice were tested by (PCR) method as described previously (Zhang et al., 2002b) .
Lung tumor bioassay in A/J mice
For complete chemoprevention protocol, 5-week-old A/J mice were maintained in an environmentally controlled room (24711C, 12/12 h light/dark cycle), housed four per cage, in plastic cages with hardwood bedding and dust covers, and received AIN-76A Purified Diet, 100000 (Dyets Inc., Bethlechem, PA, USA) and water ad libitum. The mice were randomized into two groups of 15 animals each (Control and Treatment), prior to the beginning of the study. Two sets of pellets were designed to give 40 mg/kg/body weight/day, based on an average starting body weight of 22.5 g for the first month, and 27.5 g for months 2-4. The mice were anesthetized with one i.p. injection of a sterile solution of Ketamine (80 mg/ kg) and xylazine (16 mg/kg). The pellets were inserted under aseptic conditions between the ear and shoulder blade, alternating sides each month, and the incision was closed with a single sterile wound clip. The first dose of NNK was given on day 7, i.p. at 100 mg/kg/body weight. The second i.p. dose of NNK was delivered on Day 14. The health and weight of the animals were monitored on a biweekly basis for the duration of the experiment. Animals were terminated by CO 2 asphyxiation on day 120, from the start of the chemoprevention regimen.
For late treatment protocol, 4-week-old, male A/J mice were given one i.p. injection of NNK, at 100 mg/kg body weight in PBS, and monitored for 18 weeks. On the first day of FTI-276 treatment (18 weeks after NNK administration), the animals were randomized into treatment groups as follows: Group 1, 12 mice treated with FTI-276 time-release pellet; Group 2, 12 mice treated with pellet matrix control. The custom-made time-release pellets contained the equivalent concentration of FTI-276 to deliver 1.25 mg/day for 30 days, based on 50 mg/kg /day to a 25 g mouse (Group 1), or matrix alone (Group 2). The pellets were inserted under sterile conditions, one per animal, s.c., at the right dorsal base of the neck. At the end of the fourth week of treatment with FTI-276, the mice were euthanized by CO 2 asphyxiation.
To maintain the integrity of the DNA and RNA in fresh tumors, the lungs were harvested and evaluated by one investigator so that the tumors could be collected and snap frozen as quickly as possible. When available, 1-5 fresh tumors and a small portion of uninvolved lung were collected immediately upon termination and snap frozen. Blood samples were obtained from a representative number of mice for evaluation of circulating FTI-276 by HPLC. The lungs were fixed in Tellyesniczky's (90% ethanol (70% v/v), 5% glacial acetic acid, 5% formalin (10% v/v buffered formalin)) overnight, and then kept in 70% ethanol for evaluation prior to paraffin embedding. The fixed lungs were evaluated by at least two investigators, under a dissecting microscope to obtain the fixed surface tumor count, and individual tumor size was measured for volume calculation based on the following formula: (mm 3 ¼ V ¼ 4/3pr 3 ). The total tumor count was obtained by adding the fixed and frozen tumor count. Unpaired Student's t-tests were run to test for significance.
Lung tumor bioassay on A/J mice harboring a dominant-negative p53 and/or heterozygous deletion of the Ink4a/Arf Six-week-old N10(A/J Â UL53-3) Â N6(A/J Â p16KO) F 1 mice were randomized into control and treatment groups based on the genotype and gender. Control mice received a single dose of 0.1 ml tricaprylin as vehicle control. Treatment groups received a single i.p. dose of B[a]P (100 mg/kg body weight). At 20 weeks after B[a]P exposure, FTI treatment groups received 0.1 ml vehicle controls and groups 9-12 were given 0.1 ml FTI s.c., (70 mg/kg/day) once daily, 5 days/week for 10 weeks. FTI was dissolved in an aqueous solution containing NaCl to adjust the osmolarity to 270-300 mosmol and sodium citrate to give a pH of 5.4. The vehicle was water similarly adjusted with NaCl and sodium citrate to achieve the desired osmolarity and pH. All animals were killed 30 weeks after exposure to carcinogens (B[a]P) by CO 2 asphyxiation. All animals were observed daily for clinical signs of ill health. Moribund mice were terminated by CO 2 . All mice were killed or found dead were necropsied, and their tissues were fixed in 10% neutral-buffered formalin.
Analysis of Kras2 mutations by PCR-direct sequencing
DNA was isolated from lung tumors using the TRIzol reagent (Gibco BRL). The sequences of PCR primers for Kras2 exons 1 and 2 have been described previously (You et al., 1989) . Briefly, a 100 ml reaction mixture containing 100 ng genomic DNA, 10 mm Tris-HCl, pH 8.5, 50 mm KCL, 2.5 mm MgCl 2 , 100 mm of each deoxyribonucleoside triphosphate (dATP, dCTP, dGTP, dTTP), 1.0 U of Taq DNA polymerase (Promega, Madison, WI, USA), and 40 pmol of each primer was overlaid with sterile mineral oil and subjected to 35 cycles of PCR amplification. Each cycle consisted of 1 min each at 941C, 551C, and 721C. The direct sequencing of PCR products was also carried out as described previously (You et al., 1989) .
Statistical analysis
Students t-test was used to determine the differences in the number and size of lung tumors per mouse between treatment and control mice. Fisher's exact test was used to determine the difference in the incidence. The significance of percent changes were calculated using Z-statistics for proportions (Z ¼ ðp p 1 Àp p 2 = ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffif p pð1 Àp pÞð1=n 1 þ 1=n 2 Þ p Þ), wherep p 1 is the proportional reduction due to FTI in the wild-type group,p p 2 is the proportional reduction due to FTIs in the transgenic groups,p p is the proportional reduction due to FTIs regardless of genotype, n 1 is the number of wild-type animals, and n 2 the number of transgenic animals. P-values corresponding to Zstatistics were looked up in a table.
